Biocorrx (BICX) versus The Competition Financial Analysis

Earnings & Valuation

This table compares Biocorrx and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Biocorrx	$10,000.00	-$5.11 million	-0.88
Biocorrx Competitors	$12.81 billion	$234.98 million	1.80

Biocorrx’s peers have higher revenue and earnings than Biocorrx. Biocorrx is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Biocorrx and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biocorrx	N/A	N/A	-226.71%
Biocorrx Competitors	-747.65%	-29.71%	-13.76%

Risk & Volatility

Biocorrx has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500. Comparatively, Biocorrx’s peers have a beta of 1.24, meaning that their average share price is 24% more volatile than the S&P 500.

Insider and Institutional Ownership

57.3% of shares of all “Medical Services” companies are held by institutional investors. 21.4% of Biocorrx shares are held by company insiders. Comparatively, 12.9% of shares of all “Medical Services” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Biocorrx peers beat Biocorrx on 6 of the 9 factors compared.

Biocorrx Company Profile

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.